As medical technology continues to evolve and bring the ultimate solutions and treatments to patients, Samsung Electronics Switzerland has contributed to the development through the development of its products.
LG has teamed up with Bottneuro AG, a Swiss MedTech startup dedicated to improving the diagnosis and treatment of Alzheimer’s disease and providing patients with an enhanced treatment and diagnosis and treatment solution. Bottneuro AG chose the Samsung Galaxy Tab S8+ 5G Enterprise Edition hardware to store and store data in the Bottneuro solution.
Powered by innovative technology
AG’s Bottneuro technology identifies areas of the brain affected by disease using data from 3D magnetic resonance imaging (MRI) and posterior emission tomography (PET). Once identified, these areas can be targeted and electronically stimulated with Miamind® Neurostimulator Technology. The Galaxy Tab S8+ 5G Enterprise Edition simplifies starting with the Bottneuro solution through a graphical interface.
Patients suffering from dementia often experience reduced cognitive function in the early stages of the disease, making it imperative for Bottneuro AG to find a device that is easy to use and understand. With an intuitive and easy-to-use interface, the Galaxy Tab S8+ 5G Enterprise Edition provides the optimal hardware solution for Bottneuro.
“We were looking for a simple and reliable solution for our application. We found it with the Galaxy Tab S8+ 5G Enterprise Edition and Samsung is giving us great support in the development,” said Julius Klaas, CTO of Bottneuro AG.
Complete solutions in one galaxy tablet
The Galaxy Tab S8+ 5G Enterprise Edition offers plenty of features and capabilities. It comes with a high resolution Super AMOLED display that provides excellent clarity for patients and healthcare providers and offers a long, reliable battery life.
Miamind® Neurostimulator also works directly with the Galaxy Tab S8+ 5G Enterprise Edition and, once the treatment is complete, the Galaxy Tab S8+ automatically transmits diagnostic and treatment information to Bottneuro AG’s Bottneuro solution via 5G data connectivity, allowing patients to remain in his comfort. In addition, the Galaxy Tab S8+ 5G Enterprise Edition can be configured in detail via Samsung Knox, keeping sensitive data and medical records private and secure.
Partners in the future
Groundbreaking innovations like this cannot happen without partnerships, and Samsung is proud to support and work with Bottneuro AG, since its launch in 2021.
“We are pleased to offer AG Bottneuro a reliable, secure and simple solution with Samsung Knox and to support the new therapeutic approach,” added Daniele Casella, Head of MX B2B Mobile at Samsung Switzerland.
The effectiveness of the new medical treatment by Bottneuro AG will be tested in several clinical studies this year. Although the treatment is not yet commercially available, Bottneuro AG and Samsung remain optimistic about the progress that can be made in treating Alzheimer’s disease.
For more information about the partnership between Bottneuro AG and Samsung, please visit LG Newsroom Switzerland, www.bottneuro.com or www.miamind.com.
